Core Viewpoint - Zhaowei Electromechanical experienced a stock price decline of 2.00% on September 3, 2023, with a current price of 120.84 CNY per share and a total market capitalization of 29.025 billion CNY [1] Financial Performance - For the first half of 2025, Zhaowei Electromechanical reported a revenue of 787 million CNY, representing a year-on-year growth of 21.93%, and a net profit attributable to shareholders of 113 million CNY, up 20.72% year-on-year [2] - The company has distributed a total of 333 million CNY in dividends since its A-share listing, with 192 million CNY distributed over the past three years [3] Stock Market Activity - The stock has seen a year-to-date increase of 64.13%, with a slight decline of 0.70% over the last five trading days and an 18.52% increase over the past 60 days [1] - Zhaowei Electromechanical has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on April 23, 2023, where it recorded a net buy of 93.537 million CNY [1] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 40.23% to 55,600, while the average circulating shares per person decreased by 28.69% to 3,709 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Penghua Carbon Neutral Theme Mixed A and Hong Kong Central Clearing Limited, while Southern CSI 1000 ETF entered the list as a new shareholder [3]

Core Viewpoint - The stock of Kaili Medical has experienced a decline in trading, with a current price of 32.15 yuan per share and a market capitalization of 13.91 billion yuan, reflecting a 9.76% increase year-to-date but a recent downward trend in the last five, twenty, and sixty days [1] Financial Performance - For the first half of 2025, Kaili Medical reported a revenue of 964 million yuan, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% year-on-year [2] - Since its A-share listing, Kaili Medical has distributed a total of 381 million yuan in dividends, with 258 million yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Kaili Medical was 14,300, a decrease of 1.46% from the previous period, while the average circulating shares per person increased by 1.48% to 30,244 shares [2] - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Guangfa Medical Care Stock A, with increases in holdings compared to the previous period [3] Business Overview - Kaili Medical, established on September 27, 2002, and listed on April 6, 2017, specializes in the research, development, production, and sales of medical diagnostic and treatment equipment [1] - The company's main revenue sources are ultrasound imaging (58.07%) and endoscopes and related treatment instruments (40.90%), with other sources contributing 1.02% [1] Market Position - Kaili Medical operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is involved in various concept segments including in vitro diagnostics and medical devices [1]

Core Viewpoint - Oupeng Vision's stock has experienced a decline in recent trading sessions, with a year-to-date drop of 5.59% and a 4.02% decrease over the last five trading days [1] Financial Performance - For the first half of 2025, Oupeng Vision reported revenue of 871 million yuan, a year-on-year decrease of 1.42%, and a net profit attributable to shareholders of 250 million yuan, down 22.93% year-on-year [2] - The company has distributed a total of 897 million yuan in dividends since its A-share listing, with 526 million yuan distributed over the past three years [3] Shareholder Information - As of August 29, 2025, the number of shareholders for Oupeng Vision was 61,700, a decrease of 3.70% from the previous period, while the average circulating shares per person increased by 3.84% to 10,832 shares [2] - Major institutional shareholders include Huabao Zhongzheng Medical ETF, Yifangda Growth Enterprise Board ETF, and Southern Zhongzheng 500 ETF, all of which have increased their holdings compared to the previous period [3] Market Activity - On September 3, Oupeng Vision's stock price was 17.68 yuan per share, with a trading volume of 72.59 million yuan and a turnover rate of 0.61% [1] - The company experienced a net outflow of 6.13 million yuan in principal funds, with significant selling pressure observed [1]

Group 1 - The core viewpoint of the news is that Ternua has shown a significant increase in stock price and trading activity, with a year-to-date increase of 33.73% and a market capitalization of 8.271 billion yuan [1] - As of September 3, Ternua's stock price reached 9.36 yuan per share, with a trading volume of 2.01 billion yuan and a turnover rate of 2.48% [1] - The company has experienced net outflows of main funds amounting to 3.0884 million yuan, with large orders showing a net buy of 53.1446 million yuan [1] Group 2 - Ternua's main business segments include outdoor products and chip business, with revenue contributions of 63.31% from outdoor clothing, 17.13% from chip products, 13.29% from outdoor footwear, 3.71% from outdoor equipment, and 2.56% from other services [1] - As of June 30, Ternua had 58,000 shareholders, an increase of 31.04%, with an average of 15,220 circulating shares per shareholder, a decrease of 23.69% [2] - For the first half of 2025, Ternua reported operating revenue of 653 million yuan, a year-on-year decrease of 7.82%, and a net profit attributable to shareholders of 20.0941 million yuan, down 76.50% year-on-year [2] Group 3 - Ternua has distributed a total of 509 million yuan in dividends since its A-share listing, with cumulative distributions of 30.4177 million yuan over the past three years [3]

Company Overview - Weigao Blood Purification Products Co., Ltd. is located in Weihai, Shandong Province, established on December 27, 2004, and listed on May 19, 2025. The company specializes in the research, production, and sales of medical products for blood purification [1][2]. Financial Performance - For the first half of 2025, Weigao Blood Purification achieved operating revenue of 1.765 billion yuan, representing a year-on-year growth of 8.52%. The net profit attributable to the parent company was 220 million yuan, with a year-on-year increase of 10.11% [2]. Stock Performance - As of September 3, Weigao Blood Purification's stock price increased by 2.04%, reaching 43.53 yuan per share, with a trading volume of 307 million yuan and a turnover rate of 18.75%. The total market capitalization is 17.908 billion yuan [1]. - Year-to-date, the stock price has risen by 5.12%, with a 12.25% increase over the last five trading days, a 9.40% increase over the last 20 days, and an 18.29% increase over the last 60 days [1]. Market Activity - The net inflow of main funds was 28.5053 million yuan, with large orders accounting for 28.07% of total purchases and 17.82% of total sales. The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on September 2, where it recorded a net buy of -16.0277 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Weigao Blood Purification was 31,400, a decrease of 47.45% from the previous period. The average number of circulating shares per person increased by 90.29% to 1,213 shares [2]. Industry Classification - Weigao Blood Purification is classified under the pharmaceutical and biological industry, specifically in the medical device and medical consumables sector. It is part of several concept sectors, including medical devices, mid-cap stocks, and newly listed stocks [2]. Revenue Composition - The company's main business revenue composition is as follows: consumables account for 77.55%, equipment for 18.25%, and other supplementary products for 2.35% [1].

Core Viewpoint - WanDong Medical's stock price has experienced fluctuations, with a year-to-date increase of 14.56% but a recent decline in the last five trading days by 3.22% [1] Company Overview - WanDong Medical, established on May 12, 1997, and listed on May 19, 1997, is located in Chaoyang District, Beijing. The company specializes in the research, manufacturing, sales of imaging medical devices, and imaging diagnostic services [1] - The main revenue composition includes 88.18% from medical device sales, 6.32% from other supplementary services, and 5.51% from labor and services [1] Financial Performance - For the first half of 2025, WanDong Medical reported a revenue of 843 million yuan, representing a year-on-year growth of 20.46%. However, the net profit attributable to shareholders decreased by 39.46% to 51.3 million yuan [2] - Cumulative cash dividends since the A-share listing amount to 769 million yuan, with 267 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.69% to 26,800, while the average circulating shares per person increased by 13.24% to 26,201 shares [2] - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and Hong Kong Central Clearing Limited, with changes in their holdings compared to the previous period [3]

Core Viewpoint - Aibo Medical's stock has experienced fluctuations, with a year-to-date decline of 12.36% and recent gains over the past few trading days, indicating potential volatility in the market [1][2]. Company Overview - Aibo Medical, established on April 21, 2010, and listed on July 29, 2020, specializes in the research, production, and sales of ophthalmic medical devices [2]. - The company's revenue composition includes: 43.86% from artificial lenses, 30.06% from contact lenses, 15.14% from orthokeratology lenses, 6.01% from other myopia control products, 2.37% from other surgical products, 1.62% from other vision care products, and 0.95% from other income [2]. Financial Performance - For the first half of 2025, Aibo Medical reported a revenue of 787 million yuan, representing a year-on-year growth of 14.72%, and a net profit attributable to shareholders of 213 million yuan, with a growth of 2.53% [2]. - The company has distributed a total of 241 million yuan in dividends since its A-share listing, with 173 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, Aibo Medical had 15,400 shareholders, an increase of 58.37% from the previous period, with an average of 12,301 circulating shares per shareholder, a decrease of 36.86% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Hua Bao Zhong Zheng Medical ETF, with notable changes in their holdings [3].

Company Overview - Yidelong Technology Co., Ltd. is located in Suzhou, Jiangsu Province, and was established on May 31, 2001. The company went public on June 22, 2017. Its main business involves providing electronic manufacturing services to clients in telecommunications, industrial control, automotive electronics, medical electronics, and consumer electronics sectors [1]. Stock Performance - On September 2, Yidelong's stock price increased by 2.01%, reaching 44.66 CNY per share, with a trading volume of 184 million CNY and a turnover rate of 2.61%. The total market capitalization is 7.165 billion CNY [1]. - As of July 31, the number of shareholders for Yidelong was 11,300, an increase of 3.67% from the previous period, while the average circulating shares per person decreased by 3.54% to 14,198 shares [1]. Financial Performance - For the first half of 2025, Yidelong achieved a revenue of 1.171 billion CNY, representing a year-on-year growth of 15.64%. The net profit attributable to shareholders was 115 million CNY, reflecting a year-on-year increase of 31.06% [1]. Dividends and Shareholding - Since its A-share listing, Yidelong has distributed a total of 413 million CNY in dividends, with 224 million CNY distributed over the past three years [2]. - As of June 30, 2025, among the top ten circulating shareholders, E Fund Kexun Mixed Fund (110029) ranked as the sixth largest shareholder with 2.1132 million shares, an increase of 146,300 shares from the previous period. E Fund Kairong Mixed Fund (006533) entered the list as the ninth largest shareholder with 1.5616 million shares [2].

Company Overview - Jinfa Technology Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on May 26, 1993. The company was listed on June 23, 2004. Its main business involves the research, production, and sales of new chemical materials [1][2]. - The company's main revenue sources are modified plastics (52.07%), trading products (20.65%), green petrochemical products (18.85%), new materials (6.29%), medical health products (1.48%), and others (0.66%) [1]. Financial Performance - For the first half of 2025, Jinfa Technology achieved operating revenue of 31.636 billion yuan, representing a year-on-year growth of 35.50%. The net profit attributable to shareholders was 585 million yuan, with a year-on-year increase of 54.12% [2]. - Since its A-share listing, the company has distributed a total of 6.740 billion yuan in dividends, with 1.136 billion yuan distributed in the last three years [3]. Stock Performance - As of September 2, Jinfa Technology's stock price was 15.50 yuan per share, with a market capitalization of 40.867 billion yuan. The stock has increased by 81.46% year-to-date, but has seen a decline of 5.31% over the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on February 20 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 203,600, a decrease of 7.98% from the previous period. The average number of circulating shares per person increased by 8.67% to 12,757 shares [2]. - Among the top ten circulating shareholders, the Southern CSI 500 ETF held 31.3089 million shares, an increase of 4.2658 million shares compared to the previous period. Conversely, Hong Kong Central Clearing Limited held 30.7447 million shares, a decrease of 423,430 shares [3].

Company Overview - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with a focus on joint prosthetics and spinal implants [1][2] - The company was established on February 12, 1998, and went public on December 30, 2021 [1] - Its main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1] Financial Performance - For the first half of 2025, Spring Medical reported a revenue of 488 million yuan, representing a year-on-year growth of 28.27% [2] - The net profit attributable to shareholders for the same period was 114 million yuan, showing a year-on-year increase of 44.85% [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Stock Performance - As of September 1, the stock price of Spring Medical increased by 5.73%, reaching 23.63 yuan per share, with a total market capitalization of 9.064 billion yuan [1] - Year-to-date, the stock has risen by 85.32%, with a 3.87% increase over the last five trading days and a 39.65% increase over the last 60 days [1] - The company experienced a net outflow of 967,900 yuan in principal funds, with large single purchases accounting for 17.75% of total transactions [1] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 17.57% to 5,920, while the average number of circulating shares per person increased by 341.41% to 48,836 shares [2] - Among the top ten circulating shareholders, Ping An Low Carbon Economy Mixed A (009878) is the fourth largest, increasing its holdings by 2.77 million shares [3] - New shareholder South Pharmaceutical Health Flexible Allocation Mixed A (000452) entered the top ten, holding 1.603 million shares [3]